top of page

KLUS Pharma is the US subsidiary of Kelun-Biotech, a China-based corporation with a broad pipeline targeting unmet needs in oncology and other serious diseases. 

Our Company
City Skyline Across The Water

KLUS Pharma is based in Princeton, NJ and is the wholly-owned U.S. subsidiary of Kelun-Biotech, a corporation based in Chengdu, China. 

Image by Tim Bogdanov

We strive to discover and develop innovative biologics for the treatment of cancer and other serious diseases, addressing unmet needs and creating affordable medicines.

Image by Michael Longmire

We have a rich pipeline of small and large molecules targeting solid tumors and other indications with multiple ongoing clinical trials. 

About KLUS
Our Approach
mab%20picture_edited.jpg

Our antibodies undergo affinity maturation, humanization, and Fc engineering, generating lead candidates with optimal efficacy and safety.

bispecific antibodies 3.jpg

Our platform supports a wide variety of bispecific designs which allows for flexibility in selecting the optimal design based on intended MOA. 

ADC.png

Our third-generation ADC platform allows for site-specific conjugation of potent warheads to antibodies, with a variety of linkers and tunable DAR. 

Sep 29, 2024

Multiple Study Results of Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) were presented at 2024 CSCO Congress.

Sep 19, 2024

Positive results from multiple studies of Kelun Biotech's TROP2 ADC (Sac-TMT) in advanced solid tumors were presented at 2024 ESMO Congress.

Sep 10, 2024

Three study abstracts for sac-TMT (TROP2 ADC) to be presented at 2024 ESMO Congress.

Recent News
bottom of page